PDL BioPharma, Inc. Accretion Expense
PDL BioPharma, Inc. reported Accretion Expense of $44.00 thousand for the 8-month period ending 2020-08-31, per its 10-Q filed 2020-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2020-11-13
- PDL BioPharma, Inc. accretion expense for the quarter ending 2020-06-30 was $5.00K.
- PDL BioPharma, Inc. accretion expense for the quarter ending 2020-03-31 was $33.00K.
- PDL BioPharma, Inc. accretion expense for the quarter ending 2019-09-30 was $79.00K.
- PDL BioPharma, Inc. accretion expense for the quarter ending 2019-06-30 was $0.00.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 8 month | Accretion Expense 9 month |
|---|---|---|---|---|
| 2020-08-31 | $44.00K 10-Q · filed 2020-11-13 | |||
| 2020-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $38.00K 10-Q · filed 2020-08-07 | ||
| 2020-03-31 | $33.00K 10-Q · filed 2020-05-11 | |||
| 2019-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $79.00K derived: sum of 2 quarters · filed 2020-11-13 | $79.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $0.00 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 |